TMDX: The Company Doubling Earnings While Trading at a PEG of 0.53
What if I told you there’s a $4.8B company that...
Grew EPS 100% last year (industry average: 30%) → Beat Q3 consensus by 78% ($0.66 vs $0.37) → Dominates a market growing 8.9% annually through 2030 → Trades at a PEG ratio of 0.53
And most retail investors have never heard of it.
TransMedics (TMDX) has quietly revolutionized organ transplantation. Their Organ Care System keeps donor hearts, lungs, and livers alive outside the body—turning previously unusable organs into lifesaving transplants.
The result? 20.9% market share, up from 13.8% in 2023. And they’re just getting started.
Read our analysis here :
I am much more negative on TMDX. I think it's a low quality business that won't hit volume or margin targets due to competitive pressures that will emerge in the next few years. My reasons below:
1) Undifferentiated business model
The NOP model actually lowers stickiness and barriers to entry. Medical devices are typically "sticky" because hospital staff need to be trained, with multi-year contracts reinforcing product adoption. The NOP model of bundling service and product - streamlining the process to a simple phone call - eliminates switching costs and commoditizes the business model.
This would be fine if the technology was somehow differentiated, but it's not. This isn't complex tech at all. And there isn't evidence to show that that TMDX is superior to OrganOx, Liver Transport, or VitaSmart in liver viability ex-vivo. OrganOx got transport approval in September of last year. The CEO responded to this clear competitive threat by saying OrganOx can't compete in transport because their device "can't fit on a plane" (paraphrasing) Not kidding - google the device right now and see if you agree with this take.
I don't believe owning a fleet of planes is a differentiator. If the ROI is there, OrganOx will undertake the capex project, or just lease the planes. The whitespace is white enough for multiple players each with fleets.
Once TMDX starts getting competed against directly, the choice for customers quickly becomes “who gives me acceptable outcomes at the lowest cost with decent service,” especially given OrganOx is roughly one‑third the cost.
2) Unrealistic Volume Target
The 10,000‑organ target is very unrealistic. It leans heavily on DCD (donation after criculatory death) growth that would require uncontrolled DCD to work and be adopted at scale, which recent U.S. data and European experience don’t really support yet. It's a very novel idea. Beyond DCD, the Company also points to an opportunity in kidney transplantation, a lower-ASP market already dominated by LifePort, which has utilized perfusion technology for decades. This is also not to mention the negative tailwinds associated with kidney transplant volumes long-term (GLP-1s lowering incidence of diabetes - the primary reason for kidney transplantation)
3) NRP is a threat
Management likes to play up NMP (normothermic machine perfusion - the tech TMDX uses) vs cold storage. This is a strawman. The real argument is NMP vs NRP (normothermic regional perfusion).
NRP can cover multiple organs per run (and thus is usually cheaper on a per-organ basis). It also shows DCD outcomes comparable to DBD—often at a lower per‑organ cost.
While NRP is used at both the hospital and organ procurement organization (OPO) levels, TransMedics is structurally limited in its ability to compete with OPO-driven NRP solutions, as the company sells exclusively to hospitals.